Galan Lithium hikes its lithium resource by 2.5x and shareholders reward it
Galan Lithium (ASX:GLN) became the latest lithium explorer to unveil an upgraded JORC Resource. But it has been a while since we saw a resource upgrade that was 2.5x higher. And shareholders are excited.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
Galan Lithium has an upgraded resource
Galan Lithium has the Hombre Muerto West Project (HMW) in Argentina. Since making an initial Resource Estimate in early 2020, it has done further exploration work at the project with success. And today it capped off the hard work by unveiling a new Mineral Resource Estimate accounting for its success.
HMW now has a resource of 5.8Mt contained lithium carbonate equivalent (LCE) at 866mg/l lithium. The total Galan Lithium Resource (including its Candelas project that also lies in Argentina) is 6.5Mt at 839mg/l lithium.
So, what is next?
Although Galan Lithium shares are down this year, they have gained ~20% this morning. Shareholders are excited not just about the resource but about the upcoming DFS in the next quarter. And with the booming demand for lithium, investor appetite for the sector is following suit.
Galan Lithium (ASX:GLN) share price chart (Graph: TradingView)
However, we think shareholders should be cautious about the economics of the project. It is located inland, 1400km from Buenos Aires, and is in a high region of the Andes at 4,000m above sea-level. Ultimately, shareholders may not have to worry about this until the Bankable Feasibility Study phase, and for now can just look forward to the DFS.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
No credit card needed and the trial expires automatically.

Blog Categories
Get Our Top 5 ASX Stocks for FY26
Recent Posts
Mesoblast (ASX:MSB) Reaches Multi-Year High as Ryoncil Revenue Targets US$30M: Is It Still a Buy?
Commercial momentum builds as Mesoblast targets two major 2026 catalysts: Adult label expansion and Revascor BLA filing. Mesoblast (ASX: MSB)…
TechnologyOne (ASX: TNE) Wins $54.7M Legal Battle: Is the 34% Dip Now a Buying Opportunity?
TechnologyOne (ASX: TNE) has finally put one of Australia’s longest-running employment disputes behind it. The Federal Court threw out a…
Austal (ASX: ASB) Secures A$1bn Defence Win: A Defensive Buy at 28x Earnings?
Austal (ASX: ASB) locked in more than A$1.16 billion in new contracts last week, cementing its position as Australia’s go-to…